| | | | | | | | | | |
|
Dockets Management
|
| Dockets Entered On June 1, /2006
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1984D-0115
|
| GUIDELINE FOR SUBMISSION OF STABILITY STUDIES OF HUMAN DR
|
|
|
| 1985D-0243
|
| GUIDELINE FORMAT/CONTENT OF CHEMISTRY MFG/CONTROLS SEC
|
|
|
| 1993D-0139
|
| Stability Testing of Biotechnological/Biological Products
|
|
|
| 1996D-0010
|
| International Conference on Harmonisation;Draft Guideline
|
|
|
| 1996D-0028
|
| Stability Testing for New Dosage Forms, (ICH)
|
|
|
| 1997D-0448
|
| Test Procedures & Acceptance Criteria for New Drug Subs.
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| 1998D-0362
|
| Stability Testing of Drug Substances and Drug Products
|
|
|
| 1998D-0374
|
| International Conference on Harmonisation; Draft Guidance
|
|
|
| 1998D-0994
|
| Draft Guidance for Industry on BACPAC I
|
|
|
| 2000D-0186
|
| M4 Common Technical Document;InterNatl Confern on Harmonisat
|
|
|
| 2000D-1418
|
| Q7A ICH Good Manufacturing Practice Guide for Active Pharmac
|
|
|
| 2001D-0361
|
| Guidance ICH Q1D Bracketing and Matrixing Designs for Stabil
|
|
|
| 2002D-0231
|
| Stability Data Pack for Registration Climatic Zones lll & IV
|
|
|
| 2002D-0237
|
| QIE Evaluation of Stability Data
|
|
|
| 2003D-0061
|
| Comparability Protocols Chemistry Manufacturing and controls
|
|
|
| 2003D-0571
|
| Guidance for Industry on Drug Substance; Chemistry, Manufacturing, and Controls Information
|
|
|
| 2004P-0557
|
| ANDA for a generic version of Efudex Cream(fluorouracil) cream
|
|
|
| 2005D-0021
|
| International Conference on Harmonisation; Draft Guidance on Q8 Pharmaceutical Development
|
|
|
| 2005N-0262
|
| Submission of Chemistry, Manufacturing, and Controls Information in a New Drug Application Under the New Pharmaceutical Quality Assessment System; Notice of Pilot Program
|
|
|
| 2005P-0377
|
| Petition to Rescind the "Generally Recognized as Safe" or GRAS Status for Aluminum Based Food Additives
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
| 2006D-0083
|
| Draft Guidance for Industry on Clinical Data Needed to Support the Licensure of Trivalent Inactivated Influenza Vaccines
|
|
|
| 2006D-0088
|
| Guidance for Industry; Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines
|
|
|
| 2006D-0198
|
| Submission of Chemistry, Manufacturing, and Controls Information for Synthetic Peptides
|
|
|
| 2006N-0202
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002
|
|
|
|
|
|
|
| 1984D-0115
|
| GUIDELINE FOR SUBMISSION OF STABILITY STUDIES OF HUMAN DR
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 2
|
|
|
| 1985D-0243
|
| GUIDELINE FORMAT/CONTENT OF CHEMISTRY MFG/CONTROLS SEC
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 1993D-0139
|
| Stability Testing of Biotechnological/Biological Products
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 2
|
|
|
| 1996D-0010
|
| International Conference on Harmonisation;Draft Guideline
|
|
| | | | | | | | |
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 1996D-0028
|
| Stability Testing for New Dosage Forms, (ICH)
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 1997D-0448
|
| Test Procedures & Acceptance Criteria for New Drug Subs.
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| LET 17738
|
| Phoenix Biologics, Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17739
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17740
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17741
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17742
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17743
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17744
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17745
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17746
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17747
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17748
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17749
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17750
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17751
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17752
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17753
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17754
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17755
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17756
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17757
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17758
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17759
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17760
|
| NBTY Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17761
|
| Mom Enterprises, Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17762
|
| Ortho Molecular Products, Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17763
|
| Ortho Molecular Products, Inc.
|
| Vol #:
|
| 164
|
|
|
| LET 17764
|
| Ortho Molecular Products, Inc.
|
| Vol #:
|
| 164
|
|
|
| 1998D-0362
|
| Stability Testing of Drug Substances and Drug Products
|
|
| | | | | | | | |
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 5
|
|
|
| 1998D-0374
|
| International Conference on Harmonisation; Draft Guidance
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 1998D-0994
|
| Draft Guidance for Industry on BACPAC I
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 2
|
|
|
| 2000D-0186
|
| M4 Common Technical Document;InterNatl Confern on Harmonisat
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 3
|
|
|
| 2000D-1418
|
| Q7A ICH Good Manufacturing Practice Guide for Active Pharmac
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 2
|
|
|
| 2001D-0361
|
| Guidance ICH Q1D Bracketing and Matrixing Designs for Stabil
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2002D-0231
|
| Stability Data Pack for Registration Climatic Zones lll & IV
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2002D-0237
|
| QIE Evaluation of Stability Data
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2003D-0061
|
| Comparability Protocols Chemistry Manufacturing and controls
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 2
|
|
|
| 2003D-0571
|
| Guidance for Industry on Drug Substance; Chemistry, Manufacturing, and Controls Information
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 3
|
|
|
| 2004P-0557
|
| ANDA for a generic version of Efudex Cream(fluorouracil) cream
|
|
|
| LET 4
|
| Valeant Pharmaceuticals International
|
| Vol #:
|
| 3
|
|
|
| 2005D-0021
|
| International Conference on Harmonisation; Draft Guidance on Q8 Pharmaceutical Development
|
|
|
| NWL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2005N-0262
|
| Submission of Chemistry, Manufacturing, and Controls Information in a New Drug Application Under the New Pharmaceutical Quality Assessment System; Notice of Pilot Program
|
|
|
| LET 11
|
| Tibotec, Inc.
|
| Vol #:
|
| 2
|
|
|
| 2005P-0377
|
| Petition to Rescind the "Generally Recognized as Safe" or GRAS Status for Aluminum Based Food Additives
|
|
|
| SUP 12
|
| Department of the Planet Earth
|
| Vol #:
|
| 5
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|